PSMD2 and lung adenocarcinoma: As can be seen in Figure 3A, the overall survival of lung adenocarcinoma patients with higher PSMD2 expression was significantly shorter than those with lower PSMD2 expression (38.2 vs. 59.7 months, p < 0.001).